Literature DB >> 9816183

Clustered p53 immunostaining: a novel pattern associated with prostate cancer progression.

G Yang1, A M Stapleton, T M Wheeler, L D Truong, T L Timme, P T Scardino, T C Thompson.   

Abstract

Abnormal p53 protein accumulation is typically defined as present when greater than 5 or 10% of cancer cells stain positively. We present a novel approach whereby immunopositivity is defined when 15 or more cells within a 300 x 400-micrometer(2) field exhibit p53 protein accumulation; a feature that we have called "clustered" staining. We assessed p53 immunostaining of moderately differentiated, clinically localized prostate cancers derived from two patient groups: those without cancer recurrence 5 years after radical prostatectomy, and those in whom cancer had recurred following radical prostatectomy. Clustered p53 immunopositivity was present in 10 (63%) of 16 patients in the recurrent group and in only 7 (21%) of 33 in the nonrecurrent group. Clustered p53 staining was clearly associated with cancer recurrence (P < 0.01). This refinement of a commonly used assay may help define the biological aggressiveness of a cancer.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9816183

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  5 in total

1.  GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy.

Authors:  Guru Sonpavde; Timothy C Thompson; Rajul K Jain; Gustavo E Ayala; Shinji Kurosaka; Kohei Edamura; Ken-ichi Tabata; Chengzhen Ren; Alexei A Goltsov; Martha P Mims; Teresa G Hayes; Michael M Ittmann; Thomas M Wheeler; Adrian Gee; Brian J Miles; Dov Kadmon
Journal:  Clin Cancer Res       Date:  2011-09-20       Impact factor: 12.531

2.  p53 and cyclooxygenase-2 expression are directly associated with cyclin D1 expression in radical prostatectomy specimens of patients with hormone-naïve prostate cancer.

Authors:  Panagiotis J Vlachostergios; Foteini Karasavvidou; Anna Patrikidou; Ioannis A Voutsadakis; Grigorios Kakkas; George Moutzouris; Elias Zintzaras; Danai D Daliani; Michael D Melekos; Christos N Papandreou
Journal:  Pathol Oncol Res       Date:  2011-07-23       Impact factor: 3.201

3.  mRTVP-1, a novel p53 target gene with proapoptotic activities.

Authors:  Chengzhen Ren; Likun Li; Alexei A Goltsov; Terry L Timme; Salahaldin A Tahir; Jianxiang Wang; Laura Garza; A Craig Chinault; Timothy C Thompson
Journal:  Mol Cell Biol       Date:  2002-05       Impact factor: 4.272

4.  Utility of tissue microarrays for profiling prognostic biomarkers in clinically localized prostate cancer: the expression of BCL-2, E-cadherin, Ki-67 and p53 as predictors of biochemical failure after radical prostatectomy with nested control for clinical and pathological risk factors.

Authors:  Joseph Nariculam; Alex Freeman; Simon Bott; Phillipa Munson; Noriko Cable; Nicola Brookman-Amissah; Magali Williamson; Roger S Kirby; John Masters; Mark Feneley
Journal:  Asian J Androl       Date:  2008-12-01       Impact factor: 3.285

5.  Correlation of p53 immunoexpression with DNA ploidy and apoptotic index in subsets of prostate cancer: A marker reiterated in progression and recurrence of prostate cancer.

Authors:  Anju Bansal; Anup Gupta; Sunita Saxena
Journal:  South Asian J Cancer       Date:  2015 Apr-Jun
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.